Convalescent plasma therapy in patients with COVID-19

Basit Öğe Kaydı
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorAta, Naim
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorBasci, Semih
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorNamdaroglu, Sinem
dc.date.accessioned2024-02-23T14:16:28Z
dc.date.available2024-02-23T14:16:28Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractIntroduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19. Method: The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively. Results: Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (?5 days, 6-10 days, 11-15 days) (p=0.001). Conclusion: CP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients.en_US
dc.identifier.doi10.1016/j.transci.2020.102955
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue1en_US
dc.identifier.pmid33011076en_US
dc.identifier.scopus2-s2.0-85092010682en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2020.102955
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12655
dc.identifier.volume60en_US
dc.identifier.wosWOS:000639152200050en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion And Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSars-Cov-2en_US
dc.subjectConvalescent Plasmaen_US
dc.subjectCovid-19en_US
dc.titleConvalescent plasma therapy in patients with COVID-19en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu